NewAmsterdam Pharma Files 8-K

Ticker: NAMSW · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1936258

Sentiment: neutral

Topics: corporate-filing, regulation-fd, financial-reporting

TL;DR

NAP filing 8-K on 9/2/25, standard corporate update.

AI Summary

NewAmsterdam Pharma Co N.V. filed an 8-K on September 2, 2025, reporting on events related to Regulation FD disclosure and financial statements. The filing confirms the company's legal name, incorporation in The Netherlands, and principal executive offices located at Gooimeer 2-35, Naarden, The Netherlands.

Why It Matters

This 8-K filing provides official updates on NewAmsterdam Pharma's corporate status and regulatory disclosures, which are important for investors tracking the company's compliance and financial reporting.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for NewAmsterdam Pharma Co N.V.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report on Financial Statements and Exhibits.

On what date was this 8-K report filed or effective?

The report was filed as of and the date of the earliest event reported is September 2, 2025.

Where are NewAmsterdam Pharma Co N.V.'s principal executive offices located?

The principal executive offices are located at Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.

What is the Commission File Number for NewAmsterdam Pharma Co N.V.?

The Commission File Number for NewAmsterdam Pharma Co N.V. is 001-41562.

What is the former name of NewAmsterdam Pharma Co N.V. and when did the name change occur?

The former company name was NewAmsterdam Pharma Co B.V., and the date of the name change was July 1, 2022.

Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-09-02 08:30:37

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 2, 2025, NewAmsterdam Pharma Company N.V. (the Company) posted an updated corporate investor presentation on its website ( https://www.newamsterdampharma.com ). A copy of the corporate investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained on, or that can be accessed from, the Company's website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 NewAmsterdam Pharma Company N.V. Corporate Presentation, dated September 2, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. Date: September 2, 2025 By: /s/ Michael Davidson Name: Michael Davidson, M.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing